Literature DB >> 8380726

Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise.

M J Boyle1, E Vasak, M Tschuchnigg, J J Turner, T Sculley, R Penny, D A Cooper, B Tindall, W A Sewell.   

Abstract

Epstein-Barr virus (EBV) has been associated with Hodgkin's disease (HD) in up to 50% of cases, but the subtype of EBV involved has only recently been studied. In this report, biopsy samples from 30 patients with HD were assessed for EBV sequences using both the polymerase chain reaction (PCR) and in situ hybridization (ISH). EBV sequences were localized to the malignant Reed-Sternberg cells and their mononuclear variants (Hodgkin's cells) in 9 of the 30 cases, with 7 demonstrating A-type and 2 B-type EBV sequences. Both of the patients with B-type EBV-associated HD had features to suggest pre-existing immune compromise: one was infected with human immunodeficiency virus (HIV) and had severe CD4+ T-lymphocyte depletion; the other was a debilitated elderly patient with dementia. A previous study suggested that A-type EBV alone is associated with HD and the finding of predominantly A-type EBV in the present series is in keeping with this report. The presence of B-type EBV in the HD of patients with pre-existing immunodeficiency, taken together with the recent report that B-type EBV occurs in HIV-associated non-Hodgkin's lymphoma, suggests that B-type EBV may be an important human pathogen in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Epstein-Barr virus in malignancies in renal transplant recipients in Japan.

Authors:  Y Hoshida; Y Tomita; M Ohsawa; X Ning; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Detection and characterization of Epstein-Barr virus in clinical specimens.

Authors:  R F Ambinder; R B Mann
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

3.  Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease.

Authors:  A Santón; A I Manzanal; E Campo; C Bellas
Journal:  Clin Mol Pathol       Date:  1995-08

4.  Lymphotropic herpes virus (EBV, HHV-6, HHV-8) DNA sequences in HIV negative Castleman's disease.

Authors:  P Barozzi; M Luppi; L Masini; R Marasca; M Savarino; M Morselli; M G Ferrari; M Bevini; G Bonacorsi; G Torelli
Journal:  Clin Mol Pathol       Date:  1996-08

Review 5.  The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas.

Authors:  M Weinreb; P J Day; F Niggli; J E Powell; F Raafat; P B Hesseling; J W Schneider; P S Hartley; F Tzortzatou-Stathopoulou; E R Khalek; A Mangoud; U R El-Safy; F Madanat; M Al Sheyyab; C Mpofu; T Revesz; R Rafii; K Tiedemann; K D Waters; J C Barrantes; A Nyongo; M S Riyat; J R Mann
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

6.  The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood.

Authors:  A Claviez; M Tiemann; J Peters; H Kreipe; R Schneppenheim; R Parwaresch
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

7.  Nasopharyngeal carcinoma: an EBV-associated tumour not significantly influenced by HIV-induced immunosuppression. The AIDS/Cancer Working Group.

Authors:  M Melbye; T R Coté; D West; L Kessler; R J Biggar
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.